With last week’s news that pharmaceutical giants Pfizer Inc. and Allergan plc will join together in a tax inversion valued at $160 billion, 2015 appears to be the year of the deal. The transaction brings total M&A value to $3.82 trillion for the year to date—4.3 percent higher than the record set in 2007, according to Mergermarket data.
The combination—the second-largest merger in history after Vodafone’s 1999 purchase of Mannesmann for about $172 billion—could have ramifications around the globe, pushing up drug prices and spurring more such deals in the fast-consolidating health care sector and other fields.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
